[1] SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
[2] CARLOMAGNO N, INCOLLINGO P, TAMMARO V, et al. Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. Biomed Res Int. 2017;2017:7869802.
[3] CHAN WL, YUEN KK, SIU SW, et al. Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017; 116:68-81.
[4] CLARKE MF, DICK JE, DIRKS PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66(19):9339-9344.
[5] GZIL A, ZARĘBSKA I, BURSIEWICZ W, et al. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Rep. 2019;46(6):6629-6645.
[6] BRUNGS D, AGHMESHEH M, VINE KL, et al. Gastric cancer stem cells: evidence, potential markers, and clinical implications. J Gastroenterol. 2016;51(4):313-326.
[7] WANG D, LU P, ZHANG H, et al. Correction: Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 2021;12(10):1024-1025.
[8] 马颖光,张自森,于泳,等.miR-513a-3p靶向鼠双微体基因2对胃癌细胞增殖迁移侵袭的影响[J].中华肿瘤杂志,2020,32(1):30-36.
[9] 孙梦瑶,蔡思,王杰,等.外泌体miRNAs在胃癌中的作用[J].中华检验医学杂志,2018,41(7):499-502.
[10] MI Y, ZHANG D, JIANG W, et al. miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. Cancer Lett. 2017;389:11-22.
[11] TROSCHEL FM, BÖHLY N, BORRMANN K, et al. miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumour Biol. 2018;40(8):1010428318791887.
[12] ZHANG GF, WU JC, WANG HY, et al. Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE. Biosci Rep. 2020;40(9): BSR20194509.
[13] 龚立刚,艾成思,王梦萍.miR-486-5p靶向FOXO1抑制结肠癌干细胞干性的初步研究[J].安徽医科大学学报,2020,55(4):528-533.
[14] JIN HF, WANG JF, SHAO M, et al. Down-Regulation of miR-7 in Gastric Cancer Is Associated With Elevated LDH-A Expression and Chemoresistance to Cisplatin. Front Cell Dev Biol. 2020;8:555937.
[15] HU C, ZHU S, WANG J, et al. Schistosoma japonicum MiRNA-7-5p Inhibits the Growth and Migration of Hepatoma Cells via Cross-Species Regulation of S-Phase Kinase-Associated Protein 2. Front Oncol. 2019;9:175.
[16] 章凯,王建洪,罗小邹.miRNA-7在鼻咽癌中的表达及临床意义[J].中国耳鼻咽喉头颈外科,2018,25(9):478-480.
[17] 刘华松,来金宇,郭家龙,等.miRNA-7过表达对食管癌细胞TE-1顺铂敏感性的影响及机制研究[J].湖北医药学院学报,2019,38(4): 356-360.
[18] 王妹,姜钧耀,杜雨軒,等.miR-7低表达导致非小细胞肺癌细胞吉非替尼耐药的作用机制[J].医学研究生学报,2020,33(5):460-465.
[19] YE T, YANG M, HUANG D, et al. MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res. 2019;38(1):55.
[20] XIE J, CHEN M, ZHOU J, et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 2014;31(4):1715-1722.
[21] 谷泽慧,任立群,李琪,等.奥沙利铂通过调控miRNA-7-5p/RAF-1促进胃癌SGC-7901细胞凋亡的研究[J].肿瘤防治研究,2020,47(3): 175-180.
[22] LIN J, LIU Z, LIAO S, et al. Elevated microRNA-7 inhibits proliferation and tumor angiogenesis and promotes apoptosis of gastric cancer cells via repression of Raf-1. Cell Cycle. 2020;19(19):2496-2508.
[23] 葛雯.肿瘤干细胞与microRNA的关系[J].中国医药指南,2015,13(1): 47-48.
[24] TAKAISHI S, OKUMURA T, TU S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27(5): 1006-1020.
[25] BERINDAN-NEAGOE I, MONROIG PDEL C, PASCULLI B, et al. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64(5):311-336.
[26] XUE X, FEI X, HOU W, et al. miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. Cancer Lett. 2018;412:170-178.
[27] ZHU Y, GU J, LI Y, et al. MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. Cancer Lett. 2018;412:59-68.
[28] SUN X, LI J, SUN Y, et al. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget. 2016;7(33):53558-53570.
[29] XU N, LIAN YJ, DAI X, et al. miR-7 Increases Cisplatin Sensitivity of Gastric Cancer Cells Through Suppressing mTOR. Technol Cancer Res Treat. 2017;16(6):1022-1030.
[30] ZHOU N, HAO S, HUANG Z, et al. MiR-7 inhibited peripheral nerve injury repair by affecting neural stem cells migration and proliferation through cdc42. Mol Pain. 2018;14:1744806918766793.
[31] CHANG YL, ZHOU PJ, WEI L, et al. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway. Oncotarget. 2015;6(27):24017-24031.
[32] JIA B, LIU W, GU J, et al. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Exp Cell Res. 2019;375(1):73-81.
[33] PAN M, LI M, YOU C, et al. Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation. J Cell Physiol. 2020;235(2):1405-1416.
[34] NGUYEN PH, GIRAUD J, CHAMBONNIER L, et al. Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. Clin Cancer Res. 2017;23(6):1586-1597.
[35] ISHIMOTO T, NAGANO O, YAE T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387-400.
[36] HONG Y, QIN H, LI Y, et al. FNDC3B circular RNA promotes the migration and invasion of gastric cancer cells via the regulation of E-cadherin and CD44 expression. J Cell Physiol. 2019;234(11):19895-19910.
[37] ZENG JF, MA XQ, WANG LP, et al. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol. 2017;23(13):2337-2345.
[38] LIU G, LIU GX, FANG Y,et al. Clinicopathological and prognostic value of CD24 expression in breast cancer: a meta-analysis. Int J Biol Markers. 2017;32(2):e182-e189.
[39] WANG JL, GUO CR, SU WY,et al. CD24 Overexpression Related to Lymph Node Invasion and Poor Prognosis of Colorectal Cancer. Clin Lab. 2018; 64(4):497-505.
[40] LI Y, WANG R, XIONG S, et al. Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling. J Mol Med (Berl). 2019;97(2):243-255.
[41] WANG YC, WANG JL, KONG X, et al. CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation. Apoptosis. 2014;19(4):643-656.
[42] TAKAHASHI M, NAKAJIMA M, OGATA H, et al. CD24 expression is associated with progression of gastric cancer. Hepatogastroenterology. 2013;60(124):653-658.
[43] DENG W, GU L, LI X, et al. CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells. J Transl Med. 2016; 14:32.
[44] FENG S, ZHENG Z, FENG L, et al. Proton pump inhibitor pantoprazole inhibits the proliferation, self‑renewal and chemoresistance of gastric cancer stem cells via the EMT/β‑catenin pathways. Oncol Rep. 2016;36(6):3207-3214.
[45] ZHANG C, LI C, HE F, et al. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;137(11):1679-1686.
[46] BASATI G, MOHAMMADPOUR H, EMAMI RAZAVI A. Association of High Expression Levels of SOX2, NANOG, and OCT4 in Gastric Cancer Tumor Tissues with Progression and Poor Prognosis. J Gastrointest Cancer. 2020;51(1):41-47.
[47] XIAO Y, PAN J, GENG Q, et al. LncRNA MALAT1 increases the stemness of gastric cancer cells via enhancing SOX2 mRNA stability. FEBS Open Bio. 2019;9(7):1212-1222.
[48] LI L, WEI X, WU B, et al. siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells. Oncol Lett. 2017;13(5):3014-3024.
|